

FSD Pharma

01:39 03 Jan 2020

FSD Pharma bolsters management team with three key hires

FSD Pharma Inc (CSE:HUGE) (OTCMKTS:FSDDF), a specialty pharmaceutical research company focused on cannabinoids, said Thursday that it has strengthened its management team by appointing three key executives.

In a statement, the company said it tapped Donal Carroll, as chief financial officer and Dr Sandra Lottes, as vice president and head of clinical research of the BioSciences division, at FSD Pharma. It also appointed Shahzad Shah as the company's chief operating officer.

Carroll is not new to the role as he has been the company's interim CFO since July 2018.

READ: FSD Pharma gets nod to uplist on Nasdaq

"We are very excited to have Donal Carroll transition into a permanent leadership role and are thrilled to welcome Dr Sandra Lottes and Shahzad Shah to the FSD Pharma executive team, as we begin to write the next chapter of FSD Pharma in the new year," said CEO Raza Bokhari.

"Carroll has a deep understanding of our core business and strategic outlook to transform FSD Pharma into a specialty pharmaceutical R&D company. We are fortunate to have Donal accept the role of full-time CFO, as we prepare to begin trading on the Nasdaq," he added.

Carroll earlier worked with Danaher Corporation and US-headquartered Alberto Culver, which was acquired by Unilever. He was involved with major restructuring and M&A activities, and the implementation of new internal controls and ERP systems. He has been a director at Bird River Resources since September 2017, and also serves on the board of World-Class Extractions (CSE:PUMP), where he is the chairman of the audit committee.

He has CPA-CMA credentials, as well as a Bachelor of Commerce degree from the University College Dublin, in Ireland.

Gearing up for Phase 1 safety trials

Meanwhile, Bokhari said new hire Dr Lottes brings almost "three decades" of pharmaceutical and healthcare industry experience to the company.

"Her expertise spans the drug development, commercialization and product lifecycle continuum that makes her an important and timely addition to the FSD Pharma Biosciences team as we prepare to launch Phase 1 human safety trials for our lead candidate, PP 101 micro-PEA," said Bokhari.

This is the firm's pre-clinical drug candidate for the treatment of symptoms related to fibromyalgia, a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues.

Price: 4.25

Market Cap: \$36.96 m

1 Year Share Price Graph



June 2019 November 2019 May 2020

Share Information

Code: HUGE

Listing: CSE

52 week High Low
41.205 3.51

Sector: Cannabis

Website: fsdpharma.com

Company Synopsis:

FSD Pharma is a publicly traded company on the Canadian Securities Exchange under the symbol HUGE. The Company, through its wholly-owned subsidiary FV Pharma Inc. , holds an ACMPR license to cultivate cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR).

action@proactiveinvestors.com.au

Lottes was the vice president of global clinical development and operations at United Biosource, a subsidiary of Express Scripts Inc. She also served as a key member of ESI Pharma Services leadership team responsible for the largest business unit across multiple global offices.

Dr Lottes earned an undergraduate degree in Biology from the University of Delaware and a doctorate from the Philadelphia College of Pharmacy & Science. She completed her post-doctorate fellowship in cardiovascular pharmacology at Hahnemann University Medical College. Dr Lottes has authored many articles and served on advisory boards in cardiology, gastroenterology, nephrology and biosimilars.

Boosting operational efficiency

The FSD Pharma boss also noted that the company's third hire, Shah has "a proven track record" of bringing "operational efficiency" to organizations.

"I have worked with Shahzad in the past and I expect his experience to strike the right balance between market realities and investor expectations from FV Pharma," said Bokhari.

Through its wholly-owned subsidiary FV Pharma Inc, the group is a licensed producer under Canada's Cannabis Act, having received its cultivation license in October 2017 and its sale for medical purposes license in April 2019.

In his last role, Shah was responsible for overseeing continuous improvement initiatives and managed a P&L of \$500 million in revenue.

He holds an MBA from Queen's University, Kingston Ontario, engineering and human resources diplomas from Humber College, Toronto.

FSD Pharma is focused on the research and development of cannabinoid-based treatments for several central nervous system disorders including fibromyalgia, and irritable bowel syndrome.

Headquartered at the former Kraft plant in Cobourg, Ontario, with large expansion potential, FSD also grows medical-grade cannabis at its 25,000 square foot facility in Ontario.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).